journal
https://read.qxmd.com/read/38671580/an-integrated-omics-approach-highlights-how-epigenetic-events-can-explain-and-predict-response-to-neoadjuvant-chemotherapy-and-bevacizumab-in-breast-cancer
#1
JOURNAL ARTICLE
Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N Kristensen
Treatment with the anti-angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics approach where DNA methylation profiles are integrated with gene expression and results from proteomic data in breast cancer patients to predict response to therapy and pinpoint response-related epigenetic events. Fresh-frozen tumor biopsies taken before, during, and after treatment from human epidermal growth factor receptor 2 negative non-metastatic patients receiving neoadjuvant chemotherapy with or without bevacizumab were subjected to molecular profiling...
April 26, 2024: Molecular Oncology
https://read.qxmd.com/read/38650175/kinase-activities-in-pancreatic-ductal-adenocarcinoma-with-prognostic-and-therapeutic-avenues
#2
JOURNAL ARTICLE
Andrea Vallés-Martí, Richard R de Goeij-de Haas, Alex A Henneman, Sander R Piersma, Thang V Pham, Jaco C Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti, Connie R Jiménez, Maarten F Bijlsma
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read-out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)-based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins...
April 22, 2024: Molecular Oncology
https://read.qxmd.com/read/38634213/academia-and-society-should-join-forces-to-make-anti-cancer-treatments-more-affordable
#3
JOURNAL ARTICLE
Anton Berns
Discovery research is the starting point for the development of more effective anti-cancer treatments. It requires an interdisciplinary research environment with first-class infrastructural support in which curiosity-driven research can lead to new concepts for treating cancer. Translating such research findings to clinical practice requires complementary skills and infrastructures, including high-quality clinical facilities, access to patient cohorts and participation of pharma. This complex ecosystem has yielded many new but also "me too" treatment regimens, especially in immuno-oncology resulting in an extremely high pricing of anti-cancer agents...
April 18, 2024: Molecular Oncology
https://read.qxmd.com/read/38634185/identification-of-functional-and-diverse-circulating-cancer-associated-fibroblasts-in-metastatic-castration-na%C3%A3-ve-prostate-cancer-patients
#4
JOURNAL ARTICLE
Richell Booijink, Leon W M M Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal
In prostate cancer (PCa), cancer-associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other circulating cells and their association with PCa metastasis. Here, we explored the presence of circulating CAFs (cCAFs) in metastatic castration-naïve prostate cancer (mCNPC) patients. cCAFs were stained with fibroblast activation protein (FAP), epithelial cell adhesion molecule (EpCAM), and receptor-type tyrosine-protein phosphatase C (CD45), then FAP+ EpCAM- cCAFs were enumerated and sorted using fluorescence-activated cell sorting...
April 17, 2024: Molecular Oncology
https://read.qxmd.com/read/38627210/proteome-based-molecular-subtyping-and-therapeutic-target-prediction-in-gastric-cancer
#5
JOURNAL ARTICLE
Changyuan Hu, Jiangning Song, Terry Kwok, Elizabeth V Nguyen, Xian Shen, Roger J Daly
Different molecular classifications for gastric cancer (GC) have been proposed based on multi-omics platforms with the long-term goal of improved precision treatment. However, the GC (phospho)proteome remains incompletely characterized, particularly at the level of tyrosine phosphorylation. In addition, previous multiomics-based stratification of patient cohorts has lacked identification of corresponding cell line models and comprehensive validation of broad or subgroup-selective therapeutic targets. To address these knowledge gaps, we applied a reverse approach, undertaking the most comprehensive (phospho)proteomic analysis of GC cell lines to date and cross-validating this using publicly available data...
April 16, 2024: Molecular Oncology
https://read.qxmd.com/read/38605607/manzamine-a-reduces-androgen-receptor-transcription-and-synthesis-by-blocking-e2f8-dna-interactions-and-effectively-inhibits-prostate-tumor-growth-in-mice
#6
JOURNAL ARTICLE
Dev Karan, Seema Dubey, Sumedha Gunewardena, Kenneth A Iczkowski, Manohar Singh, Pengyuan Liu, Angelo Poletti, Yeun-Mun Choo, Hui-Zi Chen, Mark T Hamann
The androgen receptor (AR) is the main driver in the development of castration-resistant prostate cancer, where the emergence of AR splice variants leads to treatment-resistant disease. Through detailed molecular studies of the marine alkaloid manzamine A (MA), we identified transcription factor E2F8 as a previously unknown regulator of AR transcription that prevents AR synthesis in prostate cancer cells. MA significantly inhibited the growth of various prostate cancer cell lines and was highly effective in inhibiting xenograft tumor growth in mice without any pathophysiological perturbations in major organs...
April 11, 2024: Molecular Oncology
https://read.qxmd.com/read/38600695/mmp-9-dependent-proteolysis-of-the-histone-h3-n-terminal-tail-a-critical-epigenetic-step-in-driving-oncogenic-transcription-and-colon-tumorigenesis
#7
JOURNAL ARTICLE
Yonghwan Shin, Sungmin Kim, Gangning Liang, Woojin An
Matrix metalloproteinase 9 (MMP-9) is a member of the MMP family and has been recently identified as a nuclear protease capable of clipping histone H3 N-terminal tails (H3NT). This MMP-9-dependent H3NT proteolysis is critical for establishing an active state of gene transcription during osteoclast differentiation and melanoma development. However, whether H3NT cleavage by MMP-9 plays a similar role in other cellular events has not been explored. Here, we dissect the functional contribution of MMP-9-dependent H3NT clipping to colonic tumorigenesis by using a combination of genome-wide transcriptome data, ChIP/ChIPac-qPCR, CRISPR/dCas9 gene-targeting system, and in vivo xenograft models...
April 10, 2024: Molecular Oncology
https://read.qxmd.com/read/38600681/tas3681-an-androgen-receptor-antagonist-prevents-drug-resistance-driven-by-aberrant-androgen-receptor-signaling-in-prostate-cancer
#8
JOURNAL ARTICLE
Shohei Yoshida, Daisuke Kajiwara, Masanao Seki, Manabu Tayama, Yuki Tanaka, Hiroya Mizutani, Ryoto Fujita, Keisuke Yamamura, Shigeo Okajima, Masanori Asai, Kazuhisa Minamiguchi
Second-generation androgen receptor (AR) signaling inhibitors (ARSIs), such as abiraterone and enzalutamide, prolong the life of patients with castration-resistant prostate cancer (CRPC). However, patients receiving ARSIs ultimately develop resistance through various complex mechanisms, including AR mutations, constitutively active AR-splice variants (AR-Vs), and AR overexpression. Here, we characterized a novel AR pure antagonist, TAS3681, which inhibits AR transcriptional activity and downregulates AR-full length (AR-FL) and AR-Vs...
April 10, 2024: Molecular Oncology
https://read.qxmd.com/read/38590214/a-guide-to-ferroptosis-in-cancer
#9
REVIEW
Fatma Isil Yapici, Christina M Bebber, Silvia von Karstedt
Ferroptosis is a newly identified iron-dependent type of regulated cell death that can also be regarded as death caused by the specific collapse of the lipid antioxidant defence machinery. Ferroptosis has gained increasing attention as a potential therapeutic strategy for therapy-resistant cancer types. However, many ferroptosis-inducing small molecules do not reach the pharmacokinetic requirements for their effective clinical use yet. Nevertheless, their clinical optimization is under development. In this review, we summarize the current understanding of molecular pathways regulating ferroptosis, how cells protect themselves from the induction of ferroptotic cell death, and how a better understanding of cancer cell metabolism can represent vulnerabilities for ferroptosis-based therapies...
April 8, 2024: Molecular Oncology
https://read.qxmd.com/read/38572507/drd1-suppresses-cell-proliferation-and-reduces-egfr-activation-and-pd-l1-expression-in-nsclc
#10
JOURNAL ARTICLE
Christopher E Grant, Amy L Flis, Leila Toulabi, Adriana Zingone, Emily Rossi, Krist Aploks, Heather Sheppard, Bríd M Ryan
Dopamine (DA) acts in various key neurological and physiological processes as both a neurotransmitter and circulating hormone. Over the past several decades, the DA signaling network has been shown to regulate the progression of several types of solid tumors, and considerable evidence has shown it is a druggable pathway in the cancer cell context. However, the specific activity and effect of these pathway components appears to be tissue-type and cell-context-dependent. In the present study, expression and methylation of dopamine receptor D1 (DRD1) were measured using RNA sequencing (RNAseq) and reverse transcription polymerase chain reaction (RT-PCR) in non-small cell lung cancer (NSCLC) samples, and validated using publicly available datasets, including The Cancer Genome Atlas (TCGA)...
April 4, 2024: Molecular Oncology
https://read.qxmd.com/read/38567664/the-alcatraz-strategy-a-roadmap-to-break-the-connectivity-barrier-in-malignant-brain-tumours
#11
REVIEW
Matthias Schneider, Anna-Laura Potthoff, Georg Karpel-Massler, Patrick Schuss, Markus D Siegelin, Klaus-Michael Debatin, Hugues Duffau, Hartmut Vatter, Ulrich Herrlinger, Mike-Andrew Westhoff
In recent years, the discovery of functional and communicative cellular tumour networks has led to a new understanding of malignant primary brain tumours. In this review, the authors shed light on the diverse nature of cell-to-cell connections in brain tumours and propose an innovative treatment approach to address the detrimental connectivity of these networks. The proposed therapeutic outlook revolves around three main strategies: (a) supramarginal resection removing a substantial portion of the communicating tumour cell front far beyond the gadolinium-enhancing tumour mass, (b) morphological isolation at the single cell level disrupting structural cell-to-cell contacts facilitated by elongated cellular membrane protrusions known as tumour microtubes (TMs), and (c) functional isolation at the single cell level blocking TM-mediated intercellular cytosolic exchange and inhibiting neuronal excitatory input into the malignant network...
April 3, 2024: Molecular Oncology
https://read.qxmd.com/read/38564603/subpar-reporting-of-pre-analytical-variables-in-rna-focused-blood-plasma-studies
#12
REVIEW
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock
Extracellular RNA (cell-free RNA; exRNA) from blood-derived liquid biopsies is an appealing, minimally invasive source of disease biomarkers. As pre-analytical variables strongly influence exRNA measurements, their reporting is essential for meaningful interpretation and replication of results. The aim of this review was to chart to what extent pre-analytical variables are documented, to pinpoint shortcomings and to improve future reporting. In total, 200 blood plasma exRNA studies published in 2018 or 2023 were reviewed for annotation of 22 variables associated with blood collection, plasma preparation, and RNA purification...
April 2, 2024: Molecular Oncology
https://read.qxmd.com/read/38561976/circulating-cell-free-dna-methylation-based-multi-omics-analysis-allows-early-diagnosis-of-pancreatic-ductal-adenocarcinoma
#13
JOURNAL ARTICLE
Guochao Zhao, Ruijingfang Jiang, Ying Shi, Suizhi Gao, Dansong Wang, Zhilong Li, Yuhong Zhou, Jianlong Sun, Wenchuan Wu, Jiaxi Peng, Tiantao Kuang, Yefei Rong, Jie Yuan, Shida Zhu, Gang Jin, Yuying Wang, Wenhui Lou
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 7.2% in China. However, effective approaches for diagnosis of PDAC are limited. Tumor-originating genomic and epigenomic aberration in circulating free DNA (cfDNA) have potential as liquid biopsy biomarkers for cancer diagnosis. Our study aims to assess the feasibility of cfDNA-based liquid biopsy assay for PDAC diagnosis. In this study, we performed parallel genomic and epigenomic profiling of plasma cfDNA from Chinese PDAC patients and healthy individuals...
April 1, 2024: Molecular Oncology
https://read.qxmd.com/read/38561242/oncolytic-adenoviruses-and-immunopeptidomics-a%C3%A2-convenient-marriage
#14
JOURNAL ARTICLE
Marc Garcia-Moure, Andrew G Gillard, Marta M Alonso, Juan Fueyo, Candelaria Gomez-Manzano
Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of tumor-associated antigens (TAAs) that might induce an anti-tumor immunity. Due to their immunostimulatory effect, OVs have been explored for cancer vaccination against specific TAAs. However, this approach usually requires genetic modification of the virus and the production of a new viral vector for each target, which is difficult to implement for low prevalent antigens...
April 1, 2024: Molecular Oncology
https://read.qxmd.com/read/38558505/tace-inhibition-a-promising-therapeutic-intervention-against-aatf-mediated-steatohepatitis-to-hepatocarcinogenesis
#15
JOURNAL ARTICLE
Akshatha N Srinivas, Diwakar Suresh, Prashant M Vishwanath, Suchitha Satish, Prasanna K Santhekadur, Saisudha Koka, Divya P Kumar
Metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma (MASH-HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions. We previously identified that tumor necrosis factor-alpha (TNF-α) upregulated apoptosis antagonizing transcription factor (AATF) in MASH. Here, we investigated the effect of TNF-α converting enzyme (TACE) inhibition as a promising targeted therapy against AATF-mediated steatohepatitis to hepatocarcinogenesis...
April 1, 2024: Molecular Oncology
https://read.qxmd.com/read/38533616/the-one-carbon-metabolic-enzyme-mthfd2-promotes-resection-and-homologous-recombination-after-ionizing-radiation
#16
JOURNAL ARTICLE
Petra Marttila, Nadilly Bonagas, Christina Chalkiadaki, Hannah Stigsdotter, Korbinian Schelzig, Jianyu Shen, Crystal M Farhat, Amber Hondema, Julian Albers, Elisée Wiita, Azita Rasti, Ulrika Warpman Berglund, Ana Slipicevic, Oliver Mortusewicz, Thomas Helleday
The one-carbon metabolism enzyme bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is among the most overexpressed proteins across tumors and is widely recognized as a promising anticancer target. While MTHFD2 is mainly described as a mitochondrial protein, a new nuclear function is emerging. Here, we observe that nuclear MTHFD2 protein levels and association with chromatin increase following ionizing radiation (IR) in an ataxia telangiectasia mutated (ATM)- and DNA-dependent protein kinase (DNA-PK)-dependent manner...
March 27, 2024: Molecular Oncology
https://read.qxmd.com/read/38520404/correction-to-hnrnp-a1-binds-to-the-ires-of-meloe-1-antigen-to-promote-meloe-1-translation-in-stressed-melanoma-cells
#17
(no author information available yet)
No abstract text is available yet for this article.
March 23, 2024: Molecular Oncology
https://read.qxmd.com/read/38520049/pharmacological-degradation-of-atr-induces-antiproliferative-dna-replication-stress-in-leukemic-cells
#18
JOURNAL ARTICLE
Anita G Kansy, Ramy Ashry, Al-Hassan M Mustafa, Abdallah M Alfayomy, Markus P Radsak, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H Krämer
Mammalian cells replicate ~ 3 × 109 base pairs per cell cycle. One of the key molecules that slows down the cell cycle and prevents excessive DNA damage upon DNA replication stress is the checkpoint kinase ataxia-telangiectasia-and-RAD3-related (ATR). Proteolysis-targeting-chimeras (PROTACs) are an innovative pharmacological invention to molecularly dissect, biologically understand, and therapeutically assess catalytic and non-catalytic functions of enzymes. This work defines the first-in-class ATR PROTAC, Abd110/Ramotac-1...
March 22, 2024: Molecular Oncology
https://read.qxmd.com/read/38520041/tumour-immunogenicity-goes-with-the-mitochondrial-electron-flow
#19
JOURNAL ARTICLE
Asma Ahmed, Stephen W G Tait
Mitochondrial metabolism and electron transport chain (ETC) function are essential for tumour proliferation and metastasis. However, the impact of ETC function on cancer immunogenicity is not well understood. In a recent study, Mangalhara et al. found that inhibition of complex II leads to enhanced tumour immunogenicity, T-cell-mediated cytotoxicity and inhibition of tumour growth. Surprisingly, this antitumour effect is mediated by succinate accumulation affecting histone methylation. Histone methylation promotes the transcriptional upregulation of major histocompatibility complex-antigen processing and presentation (MHC-APP) genes in a manner independent of interferon signalling...
March 22, 2024: Molecular Oncology
https://read.qxmd.com/read/38519839/minimally-invasive-biopsy-based-diagnostics-in-support-of-precision-cancer-medicine
#20
REVIEW
Bo Franzén, Gert Auer, Rolf Lewensohn
Precision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine-needle aspiration biopsy-based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide support for FNA-based molecular cytology having a significant potential to replace core needle biopsy (CNB) as a patient-friendly potent technique for tumor sampling for various tumor types. This is not only because CNB is a more traumatic procedure and may be associated with more complications compared to FNA-based sampling, but also due to the recently developed molecular methods used with FNA...
March 22, 2024: Molecular Oncology
journal
journal
41656
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.